---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056852"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:23:10.858617+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics Q1 revenue $1.9M; $391M cash; advances FT819 in SLE, halts FT576 expansion

## Summary
- Cash, equivalents & investments: $391.1M as of March 31, 2024, including ~$80M offering and ~$20M private placement.
- Q1 revenue $1.9M (collaboration with Ono); GAAP operating expenses $53.0M (R&D $32.1M, G&A $20.9M, incl $11M stock comp).
- First SLE patient treated with FT819 CAR T; dose escalation completed in BCM; FT819 development to focus exclusively on autoimmunity.
- FT522 enrollment opened without conditioning chemotherapy in Phase 1 BCL; IND for autoimmunity planned mid-2024.
- FT576 dose escalation completed in multiple myeloma; company will not advance to Phase 1 dose expansion; evaluating next-gen BCMA candidates.

## SEC filing metadata
- accession: 0000950170-24-056852
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/0000950170-24-056852-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/fate-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056852
- JSON: https://secwatch.observer/filing/0000950170-24-056852.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056852.txt

## Key facts
- Earnings Releases
  FATE THERAPEUTICS INC reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017024056852/0000950170-24-056852-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.